Boston Scientific Corporation (BSX)
USD 88.03
(-2.65%)
USD 88.03
(-2.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.34 Billion USD | 42.09% |
| 2022 | 1.64 Billion USD | -19.29% |
| 2021 | 2.04 Billion USD | 95.69% |
| 2020 | 1.04 Billion USD | -31.23% |
| 2019 | 1.51 Billion USD | 0.8% |
| 2018 | 1.5 Billion USD | 17.2% |
| 2017 | 1.28 Billion USD | 187.47% |
| 2016 | 447 Million USD | 236.7% |
| 2015 | -327 Million USD | -209.36% |
| 2014 | 299 Million USD | 149.17% |
| 2013 | 120 Million USD | 103.1% |
| 2012 | -3.86 Billion USD | -527.88% |
| 2011 | 904 Million USD | 237.8% |
| 2010 | -656 Million USD | 26.62% |
| 2009 | -894 Million USD | 41.8% |
| 2008 | -1.53 Billion USD | -10871.43% |
| 2007 | -14 Million USD | 99.53% |
| 2006 | -2.94 Billion USD | -404.65% |
| 2005 | 968 Million USD | -38.5% |
| 2004 | 1.57 Billion USD | 125.82% |
| 2003 | 697 Million USD | 14.26% |
| 2002 | 610 Million USD | 510.0% |
| 2001 | 100 Million USD | -85.19% |
| 2000 | 675 Million USD | -6.9% |
| 1999 | 725 Million USD | 425.99% |
| 1998 | -222.4 Million USD | -153.62% |
| 1997 | 414.8 Million USD | 21.36% |
| 1996 | 341.8 Million USD | 19.93% |
| 1995 | 285 Million USD | 119.23% |
| 1994 | 130 Million USD | 19.71% |
| 1993 | 108.6 Million USD | 17.03% |
| 1992 | 92.8 Million USD | 31.63% |
| 1991 | 70.5 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 693 Million USD | 18.66% |
| 2024 Q3 | 718 Million USD | -1.87% |
| 2024 Q2 | 747 Million USD | 7.79% |
| 2023 Q2 | 514 Million USD | -6.88% |
| 2023 Q4 | 584 Million USD | -15.73% |
| 2023 Q1 | 552 Million USD | -5.8% |
| 2023 Q3 | 693 Million USD | 34.82% |
| 2023 FY | 2.34 Billion USD | 42.09% |
| 2022 Q4 | 586 Million USD | 63.69% |
| 2022 FY | 1.64 Billion USD | -19.29% |
| 2022 Q3 | 358 Million USD | -15.37% |
| 2022 Q1 | 466 Million USD | 158.89% |
| 2022 Q2 | 423 Million USD | -9.23% |
| 2021 Q2 | 262 Million USD | -29.19% |
| 2021 Q1 | 370 Million USD | 4725.0% |
| 2021 Q4 | 180 Million USD | -53.49% |
| 2021 Q3 | 387 Million USD | 47.71% |
| 2021 FY | 2.04 Billion USD | 95.69% |
| 2020 FY | 1.04 Billion USD | -31.23% |
| 2020 Q1 | 146 Million USD | -30.48% |
| 2020 Q2 | -71 Million USD | -148.63% |
| 2020 Q3 | -205 Million USD | -188.73% |
| 2020 Q4 | -8 Million USD | 96.1% |
| 2019 Q3 | 383 Million USD | -0.26% |
| 2019 FY | 1.51 Billion USD | 0.8% |
| 2019 Q4 | 210 Million USD | -45.17% |
| 2019 Q2 | 384 Million USD | -29.02% |
| 2019 Q1 | 541 Million USD | 69.59% |
| 2018 FY | 1.5 Billion USD | 17.2% |
| 2018 Q3 | 388 Million USD | -1.02% |
| 2018 Q2 | 392 Million USD | -3.69% |
| 2018 Q1 | 407 Million USD | 27.59% |
| 2018 Q4 | 319 Million USD | -17.78% |
| 2017 Q2 | 225 Million USD | -38.19% |
| 2017 FY | 1.28 Billion USD | 187.47% |
| 2017 Q3 | 377 Million USD | 67.56% |
| 2017 Q4 | 319 Million USD | -15.38% |
| 2017 Q1 | 364 Million USD | 160.0% |
| 2016 Q2 | -334 Million USD | -213.99% |
| 2016 Q1 | 293 Million USD | 208.12% |
| 2016 FY | 447 Million USD | 236.7% |
| 2016 Q3 | 348 Million USD | 204.19% |
| 2016 Q4 | 140 Million USD | -59.77% |
| 2015 Q1 | 24 Million USD | -77.57% |
| 2015 Q2 | 219 Million USD | 812.5% |
| 2015 Q3 | -299 Million USD | -236.53% |
| 2015 Q4 | -271 Million USD | 9.36% |
| 2015 FY | -327 Million USD | -209.36% |
| 2014 FY | 299 Million USD | 149.17% |
| 2014 Q4 | 107 Million USD | 67.19% |
| 2014 Q3 | 64 Million USD | 192.75% |
| 2014 Q2 | -69 Million USD | -135.03% |
| 2014 Q1 | 197 Million USD | 55.12% |
| 2013 Q4 | 127 Million USD | 23.3% |
| 2013 Q1 | -330 Million USD | -386.96% |
| 2013 Q2 | 220 Million USD | 166.67% |
| 2013 FY | 120 Million USD | 103.1% |
| 2013 Q3 | 103 Million USD | -53.18% |
| 2012 Q2 | -3.41 Billion USD | -1840.82% |
| 2012 Q1 | 196 Million USD | 15.29% |
| 2012 FY | -3.86 Billion USD | -527.88% |
| 2012 Q4 | 115 Million USD | 117.56% |
| 2012 Q3 | -655 Million USD | 80.8% |
| 2011 FY | 904 Million USD | 237.8% |
| 2011 Q1 | 296 Million USD | -14.94% |
| 2011 Q2 | 237 Million USD | -19.93% |
| 2011 Q3 | 174 Million USD | -26.58% |
| 2011 Q4 | 170 Million USD | -2.3% |
| 2010 Q3 | 251 Million USD | 8.66% |
| 2010 Q1 | -1.48 Billion USD | -20.71% |
| 2010 Q2 | 231 Million USD | 115.55% |
| 2010 Q4 | 348 Million USD | 38.65% |
| 2010 FY | -656 Million USD | 26.62% |
| 2009 Q1 | 11 Million USD | 100.46% |
| 2009 Q4 | -1.23 Billion USD | -456.81% |
| 2009 Q3 | 345 Million USD | 25.45% |
| 2009 Q2 | 275 Million USD | 2400.0% |
| 2009 FY | -894 Million USD | 41.8% |
| 2008 Q4 | -2.41 Billion USD | -8732.14% |
| 2008 Q3 | 28 Million USD | -90.76% |
| 2008 Q2 | 303 Million USD | -47.76% |
| 2008 Q1 | 580 Million USD | 234.88% |
| 2008 FY | -1.53 Billion USD | -10871.43% |
| 2007 FY | -14 Million USD | 99.53% |
| 2007 Q4 | -430 Million USD | -192.52% |
| 2007 Q3 | -147 Million USD | -152.5% |
| 2007 Q2 | 280 Million USD | -0.71% |
| 2007 Q1 | 282 Million USD | -0.7% |
| 2006 Q4 | 284 Million USD | 45.64% |
| 2006 Q3 | 195 Million USD | 104.97% |
| 2006 Q2 | -3.92 Billion USD | -889.74% |
| 2006 Q1 | 497 Million USD | 6.88% |
| 2006 FY | -2.94 Billion USD | -404.65% |
| 2005 Q4 | 465 Million USD | 238.39% |
| 2005 Q3 | -336 Million USD | -203.07% |
| 2005 Q2 | 326 Million USD | -36.45% |
| 2005 FY | 968 Million USD | -38.5% |
| 2005 Q1 | 513 Million USD | 1.79% |
| 2004 Q2 | 448 Million USD | 69.7% |
| 2004 Q4 | 504 Million USD | 40.78% |
| 2004 FY | 1.57 Billion USD | 125.82% |
| 2004 Q1 | 264 Million USD | 34.69% |
| 2004 Q3 | 358 Million USD | -20.09% |
| 2003 Q4 | 196 Million USD | 13.29% |
| 2003 Q2 | 173 Million USD | 11.61% |
| 2003 Q1 | 155 Million USD | -1.27% |
| 2003 FY | 697 Million USD | 14.26% |
| 2003 Q3 | 173 Million USD | 0.0% |
| 2002 FY | 610 Million USD | 510.0% |
| 2002 Q4 | 157 Million USD | -36.18% |
| 2002 Q3 | 246 Million USD | 200.0% |
| 2002 Q2 | 82 Million USD | -34.4% |
| 2002 Q1 | 125 Million USD | 15.74% |
| 2001 Q2 | -150 Million USD | -475.0% |
| 2001 Q4 | 108 Million USD | 5.88% |
| 2001 FY | 100 Million USD | -85.19% |
| 2001 Q1 | 40 Million USD | -71.01% |
| 2001 Q3 | 102 Million USD | 168.0% |
| 2000 Q3 | 165 Million USD | -14.06% |
| 2000 Q1 | 180 Million USD | -7.22% |
| 2000 Q2 | 192 Million USD | 6.67% |
| 2000 FY | 675 Million USD | -6.9% |
| 2000 Q4 | 138 Million USD | -16.36% |
| 1999 Q1 | 199 Million USD | 133.83% |
| 1999 Q4 | 194 Million USD | 65.81% |
| 1999 Q3 | 117 Million USD | -45.58% |
| 1999 Q2 | 215 Million USD | 8.04% |
| 1999 FY | 725 Million USD | 425.99% |
| 1998 FY | -222.4 Million USD | -153.62% |
| 1998 Q1 | 106.8 Million USD | 176.68% |
| 1998 Q2 | 117.6 Million USD | 10.11% |
| 1998 Q3 | 127.9 Million USD | 8.76% |
| 1998 Q4 | -588.2 Million USD | -559.89% |
| 1997 Q4 | 38.6 Million USD | -69.0% |
| 1997 FY | 414.8 Million USD | 21.36% |
| 1997 Q1 | 107.9 Million USD | 381.7% |
| 1997 Q2 | 138.8 Million USD | 28.64% |
| 1997 Q3 | 124.5 Million USD | -10.3% |
| 1996 Q1 | 103.1 Million USD | 80.88% |
| 1996 Q4 | 22.4 Million USD | -78.69% |
| 1996 Q3 | 105.1 Million USD | -5.57% |
| 1996 Q2 | 111.3 Million USD | 7.95% |
| 1996 FY | 341.8 Million USD | 19.93% |
| 1995 Q3 | 78.7 Million USD | 4.65% |
| 1995 Q4 | 57 Million USD | -27.57% |
| 1995 FY | 285 Million USD | 119.23% |
| 1995 Q1 | 74.2 Million USD | 96.3% |
| 1995 Q2 | 75.2 Million USD | 1.35% |
| 1994 Q4 | 37.8 Million USD | 18.87% |
| 1994 Q2 | 30.7 Million USD | 3.37% |
| 1994 Q1 | 29.7 Million USD | -6.31% |
| 1994 Q3 | 31.8 Million USD | 3.58% |
| 1994 FY | 130 Million USD | 19.71% |
| 1993 Q1 | 23.6 Million USD | -7.45% |
| 1993 Q2 | 26.2 Million USD | 11.02% |
| 1993 Q3 | 27 Million USD | 3.05% |
| 1993 Q4 | 31.7 Million USD | 17.41% |
| 1993 FY | 108.6 Million USD | 17.03% |
| 1992 FY | 92.8 Million USD | 31.63% |
| 1992 Q4 | 25.5 Million USD | 4.51% |
| 1992 Q3 | 24.4 Million USD | 10.91% |
| 1992 Q2 | 22 Million USD | 4.76% |
| 1992 Q1 | 21 Million USD | 121.94% |
| 1991 Q1 | 50.5 Million USD | 0.0% |
| 1991 Q4 | -95.7 Million USD | -259.77% |
| 1991 Q3 | 59.9 Million USD | 7.16% |
| 1991 FY | 70.5 Million USD | 0.0% |
| 1991 Q2 | 55.9 Million USD | 10.69% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 63.831% |
| Allurion Technologies Inc. | -78.07 Million USD | 3100.845% |
| Artivion, Inc. | 5.74 Million USD | -40704.598% |
| Avanos Medical, Inc. | 4.2 Million USD | -55685.714% |
| Butterfly Network, Inc. | -145.61 Million USD | 1709.093% |
| Butterfly Network, Inc. | -145.61 Million USD | 1709.093% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | -510.481% |
| Perspective Therapeutics, Inc. | -15.18 Million USD | 15532.749% |
| CONMED Corporation | 130.78 Million USD | -1691.476% |
| Edwards Lifesciences Corporation | 1.53 Billion USD | -52.728% |
| Paragon 28, Inc. | -37.3 Million USD | 6379.986% |
| Glaukos Corporation | -128.7 Million USD | 1920.513% |
| Globus Medical, Inc. | 133.14 Million USD | -1659.775% |
| Inspire Medical Systems, Inc. | -40.27 Million USD | 5918.082% |
| Integer Holdings Corporation | 167.33 Million USD | -1300.227% |
| Medtronic plc | 5.14 Billion USD | 54.452% |
| Nevro Corp. | -99.3 Million USD | 2459.327% |
| Owlet, Inc. | -28.63 Million USD | 8283.152% |
| Penumbra, Inc. | 73.55 Million USD | -3085.545% |
| Vicarious Surgical Inc. | -80.66 Million USD | 3004.569% |
| Smith & Nephew plc | 425 Million USD | -451.294% |
| Sonendo, Inc. | -57.74 Million USD | 4157.635% |
| STERIS plc | 836.11 Million USD | -180.224% |
| Stryker Corporation | 3.88 Billion USD | 39.738% |
| Vapotherm, Inc. | -39.08 Million USD | 6095.394% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | -83.376% |